[Medical treatment of Parkinson's disease].
D000547:Amantadine / Q000627:therapeutic use; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010640:Phenothiazines / Q000009:adverse effects; D011736:Pyridoxine / Q000009:adverse effects; D012110:Reserpine / Q000009:adverse effects
D010276:Parasympatholytics; D010640:Phenothiazines; D004295:Dihydroxyphenylalanine; D012110:Reserpine; D000547:Amantadine; D002262:Carboxy-Lyases; D011736:Pyridoxine
Traitement médical de la maladie de Parkinson.